Links between regimen-related toxicities in patients being treated for colorectal cancer

Current Opinion in Supportive and Palliative Care

Volumn 3, Issue 1, 2009, Pages 50-54

  Aprile, Giuseppe ^a,b   Ramoni, Marco ^c,d   Keefe, Dorothy ^e   Sonis, Stephen ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d LABORATORY FOR MOLECULAR MEDICINE   (United States)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bayesian analysis; Cluster; Colorectal cancer; Gastrointestinal toxicity; Markov network

Indexed keywords

ANTINEOPLASTIC AGENT;

BAYES THEOREM; COLORECTAL TUMOR; HUMAN; PROBABILITY; REVIEW;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; COLORECTAL NEOPLASMS; HUMANS; MARKOV CHAINS;

EID: 67650312003     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283269fdf     Document Type: Article

References (14)

1. Malizzia LJ, Tsu A. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs 2008;12:639-646.
2. Al-Dasooqi N, Bowen JM, Gibson RJ, et al. Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs 2008 [Epub ahead of print].
3. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology (Williston Park) 2006;20:21-28.
4. Walsh D, Rybicki LL Symptom clustering in advanced cancer. Support Care Cancer 2006;14:831-836.
5. Dodd MJ, Miaskowski C, Lee KA. Occurrence of symptom clusters. J Natl Cancer Inst Monogr 2004;32:76-78.
6. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol 2006;24:1459-1473.
7. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-487.
8. Aprile G, Ramoni M, Keefe D, Sonis S. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 2008;112:284-292.
9. Klausner AP, Steers WD. Corticotropin releasing factor: a mediator of emotional influences on bladder function. J Urol 2004;172:2570-2573.
10. Wu EQ, Birnbaum H, Mareva M, et al. Interstitial cystitis: cost, treatment, and co-morbidities in an employed population. Pharmacoeconomics 2006;24:55-65.
11. Buchanan DR, O'Mara AM, Kelaghan JW, et al. Challenges and recommen- dations for advancing state-of-the-science of quality of life assessment in symptom management trials. Cancer 2007;110:1621-1628.
12. Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005;37:435-440.
13. Schachter AD, Ramoni MF. Clinical forecasting in drug development. Nat Rev Drug Discov 2007;6:107-108.
14. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-284.